test directorySearch Results
Click here to search again.
Test Name:
Fibrin Degradation Products, Plasma
- SBMF No:
25231 - Performance Lab Name:
Hem-Coag - Test Mnemonic:
FSP - ABN:
Not required - CPT Code:
85362 - LOINC Code:
29991-7 - Also Known As:
FDP
FSP
Fibrin Split Products - Spec Type:
Plasma - Spec Container:
Light blue top (3.2% buffered sodium citrate) tube - Pref Vol:
1.0 mL - Min Vol:
0.5 mL - Fasting:
No - Spec Collect:
Routine venipuncture
Avoid traumatic puncture
Obtain full light blue top tube (fill to vacuum capacity)
Immediately after collection, gently invert tube to mix - Spec Process:
Promptly centrifuge 15 minutes
Carefully transfer plasma portion of specimen to separate plastic tube using a plastic pipette
Note: Buffy coat layer of sample must be avoided - Spec Store Transport:
Refrigerated (8 hours) or frozen - Spec Stability:
8 hours room temperature (20-30°C)
1 month frozen (-20°C) – Do not use frost-free units that undergo repeated freeze/thaw cycles - Spec Reject:
Citrate tube underfilled
Sample clotted or hemolyzed
Plasma not frozen within 8 hours of collection - Methodology:
Latex Agglutination - Use:
Detection of elevated fibrinogen degradation products (FDP) in serum—a valuable early diagnostic sign of an increased rate of fibrin deposition in thrombotic episodes - Clinical Significance:
Fibrinogen is a glycoprotein with a molecular weight of 340,000. It is composed of two peripheral areas, D and a central domain, E.
In vivo, thrombin converts plasma fibrinogen into insoluble fibrin, the fibrin clot being stabilized by Factor XIII. Plasmin splits fibrinogen as well as fibrin into various degradation products. The fragments X and Y constitute the early split products from fibrinogen and from non-crosslinked fibrin. Fragments D and E are the late split products. The degradation of the stabilized fibrin by plasmin leads to the formation of complexes named C-oligomers (YXD/DYX, YY/DXD, DY/YD, and finally to the terminal product D-dimer.
Under normal conditions, the fibrinolytic process is localized on the fibrin clot, since alpha-antiplasmin and the plasminogen activator inhibitors prevent fibrinolysis from spreading. During disseminated intravascular coagulation (DIC), fibrinolysis spreads and becomes systemic, in which case the degradation of circulating fibrinogen will occur. Fragments that are produced are very heterogeneous: products derived from fibrin, soluble complexes, degradation products from fibrinogen and from non-stabilized fibrin.
An abnormal fibrinolytic and/or fibrinogenolytic activity shown by high levels of FDP in plasma can also be found in clinical states, such as: eclampsia, alcoholic cirrhosis, carcinoma (promyelocytic leukemia), post-operative complications, cardiac, renal, and hepatic disorders, fibrinolysis, pulmonary embolism, and deep vein thrombosis (DVT).
A persistently elevated level of FDP indicates that the fibrinogenolytic or fibrinolytic process is continuing and suggests that the causative agent continues to exert its effect. - Reference Range:
Less than 5 µg/mL - Day Run:
Sun-Sat (daily) - Time Run:
As received - Time Reported:
4 hours - Test Type:
COAGULATION
